|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM300338937 |
| 003 |
DE-627 |
| 005 |
20241011231819.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2020 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.201902004
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1564.xml
|
| 035 |
|
|
|a (DE-627)NLM300338937
|
| 035 |
|
|
|a (NLM)31423670
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Wang, Jinqiang
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Glucose-Responsive Insulin and Delivery Systems
|b Innovation and Translation
|
| 264 |
|
1 |
|c 2020
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 30.12.2020
|
| 500 |
|
|
|a Date Revised 11.10.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
|
| 520 |
|
|
|a Type 1 and advanced type 2 diabetes treatment involves daily injections or continuous infusion of exogenous insulin aimed at regulating blood glucose levels in the normoglycemic range. However, current options for insulin therapy are limited by the risk of hypoglycemia and are associated with suboptimal glycemic control outcomes. Therefore, a range of glucose-responsive components that can undergo changes in conformation or show alterations in intermolecular binding capability in response to glucose stimulation has been studied for ultimate integration into closed-loop insulin delivery or "smart insulin" systems. Here, an overview of the evolution and recent progress in the development of molecular approaches for glucose-responsive insulin delivery systems, a rapidly growing subfield of precision medicine, is presented. Three central glucose-responsive moieties, including glucose oxidase, phenylboronic acid, and glucose-binding molecules are examined in detail. Future opportunities and challenges regarding translation are also discussed
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a devices
|
| 650 |
|
4 |
|a diabetes treatment
|
| 650 |
|
4 |
|a drug delivery
|
| 650 |
|
4 |
|a glucose responsive
|
| 650 |
|
4 |
|a insulin delivery
|
| 650 |
|
7 |
|a Blood Glucose
|2 NLM
|
| 650 |
|
7 |
|a Hypoglycemic Agents
|2 NLM
|
| 650 |
|
7 |
|a Insulin
|2 NLM
|
| 700 |
1 |
|
|a Wang, Zejun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yu, Jicheng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kahkoska, Anna R
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Buse, John B
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gu, Zhen
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 32(2020), 13 vom: 12. Apr., Seite e1902004
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:32
|g year:2020
|g number:13
|g day:12
|g month:04
|g pages:e1902004
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.201902004
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 32
|j 2020
|e 13
|b 12
|c 04
|h e1902004
|